OraSure Technologies Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on January 31, 2003. OraSure Technologies, Inc., a Delaware corporation, reported significant regulatory milestones regarding its OraQuick(R) Rapid HIV-1 Antibody Test.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory events and does not contain financial statements.
Material Changes and Events
- CLIA Waiver Application: On January 31, 2003, the Company submitted an application to the U.S. Food and Drug Administration (FDA) for a waiver under the Clinical Laboratory Improvements Amendments of 1988 (CLIA) for the OraQuick(R) Test.
- CLIA Waiver Approval: On the same date, the Company announced that the FDA had approved the application for the CLIA waiver for the OraQuick(R) Test.
Outlook, Risks, and Management Commentary
The filing incorporates two press releases (Exhibits 99.1 and 99.2) detailing the submission and subsequent approval of the CLIA waiver. The approval of a CLIA waiver is a critical regulatory step that typically allows the test to be performed in a broader range of settings, including physician offices and retail locations, without the need for a certified laboratory. The filing does not provide specific forward-looking guidance, risk factors, or commentary on unusual items beyond these regulatory announcements.
Key Facts for Investor Verification
- Verify the specific terms and limitations of the FDA-approved CLIA waiver for the OraQuick(R) Rapid HIV-1 Antibody Test.
- Confirm the commercial impact of the CLIA waiver on the Company's distribution channels and revenue potential.
- Review the full text of the press releases attached as Exhibits 99.1 and 99.2 for additional details on the regulatory process.